EA200601841A1 - Композиции, содержащие ингибитор jnk и циклоспорин - Google Patents

Композиции, содержащие ингибитор jnk и циклоспорин

Info

Publication number
EA200601841A1
EA200601841A1 EA200601841A EA200601841A EA200601841A1 EA 200601841 A1 EA200601841 A1 EA 200601841A1 EA 200601841 A EA200601841 A EA 200601841A EA 200601841 A EA200601841 A EA 200601841A EA 200601841 A1 EA200601841 A1 EA 200601841A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclosporin
jnk inhibitor
compositions containing
containing jnk
inhibitor
Prior art date
Application number
EA200601841A
Other languages
English (en)
Other versions
EA017893B1 (ru
Inventor
Кристиан Роммель
Пьер-Ален Витте
Original Assignee
Апплайд Рисёрч Системс Арс Холдинг Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Рисёрч Системс Арс Холдинг Н. В. filed Critical Апплайд Рисёрч Системс Арс Холдинг Н. В.
Publication of EA200601841A1 publication Critical patent/EA200601841A1/ru
Publication of EA017893B1 publication Critical patent/EA017893B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Настоящее изобретение относится к композиции, включающей ингибитор JNK и циклоспорин, прежде всего предназначенной для лечения нейрональных нарушений, аутоиммунных заболеваний и сердечно-сосудистых заболеваний.
EA200601841A 2004-04-08 2005-04-08 Композиции, содержащие ингибитор jnk и циклоспорин EA017893B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101468 2004-04-08
PCT/EP2005/051572 WO2005097116A1 (en) 2004-04-08 2005-04-08 Composition comprising a jnk inhibitor and cyclosporin

Publications (2)

Publication Number Publication Date
EA200601841A1 true EA200601841A1 (ru) 2007-04-27
EA017893B1 EA017893B1 (ru) 2013-04-30

Family

ID=34928946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601841A EA017893B1 (ru) 2004-04-08 2005-04-08 Композиции, содержащие ингибитор jnk и циклоспорин

Country Status (13)

Country Link
US (1) US20080039377A1 (ru)
EP (1) EP1850846A1 (ru)
JP (2) JP5080241B2 (ru)
KR (2) KR20120135441A (ru)
CN (1) CN1960726A (ru)
AU (2) AU2005230416B2 (ru)
BR (1) BRPI0509755A (ru)
CA (1) CA2561907A1 (ru)
EA (1) EA017893B1 (ru)
IL (1) IL178417A0 (ru)
NO (1) NO20065117L (ru)
UA (1) UA91676C2 (ru)
WO (1) WO2005097116A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
JP2009538882A (ja) * 2006-06-02 2009-11-12 メルク セローノ ソシエテ アノニム 皮膚疾患の治療のためのｊｎｋ阻害物質
US20100121057A1 (en) * 2007-04-17 2010-05-13 Merck Serono Sa Process for the Preparation of Piperazine Benzothiazoles
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009143865A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) * 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
EA027410B1 (ru) * 2011-04-29 2017-07-31 Селекта Байосайенсиз, Инк. Наноносители, вызывающие иммунную толерантность, для снижения ответной реакции цитотоксических t-лимфоцитов
EP2714026A2 (en) * 2011-06-01 2014-04-09 Stichting Het Nederlands Kanker Instituut Modulation of the ubiquitin-proteasome system (ups)
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CN104903331A (zh) * 2013-01-24 2015-09-09 山东亨利医药科技有限责任公司 Jnk抑制剂
CN105338968A (zh) 2013-05-03 2016-02-17 西莱克塔生物科技公司 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2957737A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
KR20230164862A (ko) * 2022-05-26 2023-12-05 연세대학교 산학협력단 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193267A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein JunKinases

Also Published As

Publication number Publication date
EA017893B1 (ru) 2013-04-30
KR20120135441A (ko) 2012-12-13
AU2005230416B2 (en) 2010-05-13
EP1850846A1 (en) 2007-11-07
KR20060134198A (ko) 2006-12-27
JP5080241B2 (ja) 2012-11-21
CA2561907A1 (en) 2005-10-20
BRPI0509755A (pt) 2007-10-16
AU2010212339B2 (en) 2012-07-19
CN1960726A (zh) 2007-05-09
US20080039377A1 (en) 2008-02-14
IL178417A0 (en) 2007-02-11
JP2012136550A (ja) 2012-07-19
AU2010212339A1 (en) 2010-09-09
JP2007532517A (ja) 2007-11-15
AU2005230416A1 (en) 2005-10-20
UA91676C2 (ru) 2010-08-25
WO2005097116A1 (en) 2005-10-20
NO20065117L (no) 2006-11-07

Similar Documents

Publication Publication Date Title
EA200601841A1 (ru) Композиции, содержащие ингибитор jnk и циклоспорин
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA200870019A1 (ru) Лактамовые соединения и способы их применения
BRPI0410905A (pt) inibidores de p-38
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
EA200700225A1 (ru) Аналоги тетрапептида
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA201070422A1 (ru) Производные оксадиазола
EA200700336A1 (ru) Противовирусные соединения
EA200700909A1 (ru) Азаиндолкарбоксамиды
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DK1779858T3 (da) Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
WO2005117939A3 (en) Use of GPCR54 ligands for the treatment of infertility
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
TW200724140A (en) Hydantoin compounds
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
DE602005017815D1 (de) Behandlung von entzündlicher darmerkrankung

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU